Raxibacumab treatment for inhalational anthrax after mass exposure
Part of Infections clinical trials.
This study looks at how safe and helpful raxibacumab is for people who are sick with inhalational anthrax after being exposed in a large incident. It includes all ages and also includes pregnant and breastfeeding people, focusing on outcomes from standard emergency clinical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms of inhalational anthrax caused by a confirmed mass exposure.
- You received a dose of raxibacumab as part of your care from the Strategic National Stockpile (SNS).
- You (or your parent/guardian for a child, or a legally allowed representative) can follow the study procedures.
- You are willing and able to give written consent (or child assent) to join the study.
- There are no listed reasons in the eligibility document that would automatically exclude you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes people in the U.S. who have been treated with a specific anthrax drug (raxibacumab) from the national emergency supply. It helps doctors learn more about how the drug works in real-world cases of anthrax infection.
This trial studies how safe and potentially helpful ANTHRASIL (AIGIV) is for people who have inhalational anthrax after exposure to a known source. If you have suspected or confirmed inhalational anthrax and were treated with AIGIV, you may be able to join this safety-and-benefit study.
This study tests whether a medicine called Raphamin can safely and effectively treat acute bronchitis (a chest infection with cough) in adults. Raphamin may help reduce cough and breathing problems in the early stages of this condition.
This is an observational study (doctors follow people and record outcomes) for patients with systemic anthrax who received AIGIV from the CDC. It aims to learn how safe AIGIV is and what clinical outcomes patients experience after treatment.
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
This is an early-stage safety study testing a new inhaled medication called TRL1068 in people without lung disease. Researchers want to make sure the drug is safe and well-tolerated when breathed in.
Hear when a new Infections, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.